Table 1.
Baseline characteristics of the 211 patients who performed the PR program
| Age (years) | 62.3±11.1 |
| Male, n (%) | 143 (67.7) |
| BMI (kg/m2) | 26.8±7.3 |
| FEV1 (% predicted) | 41.5±17.7 |
| FEV1/FVC (%) | 50.4±12.8 |
| Comorbidities, n (%) | |
| 0 | 3 (1.3) |
| 1 | 26 (11.5) |
| 2 | 26 (11.5) |
| ≥3 | 171 (75.7) |
| Treatments, n (%) | |
| Short-acting β2-agonists | 132 (62.5) |
| Long-acting β2-agonists | 95 (45) |
| Long-acting anticholinergic | 158 (74.9) |
| Bronchodilator–corticosteroid combination | 114 (54) |
| Inhaled corticosteroids | 42 (19.9) |
| Oral corticosteroids | 45 (21.3) |
| LTOT | 77 (36.5) |
| LTOT + NIV | 47 (22.3) |
| LTOT + CPAP | 5 (2.4) |
| NIV | 8 (3.8) |
| CPAP | 12 (5.7) |
Note: Data are expressed as mean ± standard deviation.
Abbreviations: PR, pulmonary rehabilitation; BMI, body mass index; FEV1, mean forced expiratory volume in 1 second; FVC, forced vital capacity; LTOT, long-term oxygen therapy; NIV, noninvasive ventilation; CPAP, continuous positive airway pressure.